News from the ECOG-ACRIN Cancer Research Group

November 19, 2026

Amended Trial: Lova Sun Describes Important Changes to the EA3231 Study for Patients With BRAF-Mutated Differentiated Thyroid Cancer

This phase 3 study compares BRAF-targeted therapy (dabrafenib-trametinib) to TKI therapy (cabozantinib) in patients with disease progression after standard treatments